Fortune’s Broadsheet newsletter enters a new era

CEOs attempt non-partisan approach over voting rights

Some may not see it that way, though. Read More

The never-ending Biogen Alzheimer’s drug saga delivers yet another twist

The drama of the FDA’s approval of Biogen’s Aduhelm is far from over. But what happens next? Read More

Casper turns painful even for some of its earliest startup investors

Nearly two years after mattress startup Casper’s IPO, the company} continues to hurt its venture capital shareholders. Read More